Registry and biorepository for patients with interstitial lung disease and systemic autoimmune diseases
Interstitial Lung Disease in Systemic Autoimmune Rheumatic Diseases (ILD-SARDs) Registry and Biorepository
McGill University Health Centre/Research Institute of the McGill University Health Centre · NCT05007340
This study is collecting health information and samples from patients with autoimmune diseases who have lung problems to see what causes their lung disease and find new treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 252 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | McGill University Health Centre/Research Institute of the McGill University Health Centre (other) |
| Locations | 1 site (Montreal, Quebec) |
| Trial ID | NCT05007340 on ClinicalTrials.gov |
What this trial studies
This observational study aims to create a biobank that collects clinical, pathological, laboratory, and imaging data from patients with systemic autoimmune rheumatic diseases (SARDs) who have lung involvement. By analyzing the interactions between demographic, environmental, and genetic factors, the study seeks to identify unique features and mechanisms underlying lung disease in SARDs. The collected biological samples, including blood and tissue biopsies, will facilitate research into the pathogenesis of interstitial lung disease (ILD) in these patients and may lead to novel treatment targets. The study will also explore predictive factors for the development of ILD among SARD patients.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older diagnosed with interstitial lung disease and either a defined systemic autoimmune rheumatic disease or features of autoimmunity.
Not a fit: Patients without a diagnosis of interstitial lung disease or those under 18 years old may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and treatment options for patients with lung involvement in systemic autoimmune diseases.
How similar studies have performed: Other studies have shown success in understanding the relationship between systemic autoimmune diseases and lung involvement, but this biorepository approach is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Must be aged 18 years or older 2. Diagnosis of ILD as confirmed by a chest CT 3. Either a defined SARD, an undifferentiated connective tissue disease or features of autoimmunity without meeting clinical criteria for SARD 4. Patient must be willing to give their informed consent and must be able to understand and follow the required study procedures. Exclusion Criteria: N/A
Where this trial is running
Montreal, Quebec
- RI-MUHC — Montreal, Quebec, Canada (RECRUITING)
Study contacts
- Principal investigator: Christian Pineau, MD — McGill University Health Centre/Research Institute of the McGill University Health Centre
- Study coordinator: Deborah Assayag, MD, MAS
- Email: deborah.assayag@mcgill.ca
- Phone: 514-934-1934
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Interstitial Lung Disease, Systemic Autoimmune Disease, Rheumatic Diseases, Rheumatic Arthritis, Systemic Sclerosis, Autoimmune Myositis, Systemic Lupus Erythematosus, Usual Interstitial Pneumonia